查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
妊娠毒血症诊断市场：2023 年至 2028 年预测
市场调查报告书
商品编码
1410015

妊娠毒血症诊断市场：2023 年至 2028 年预测

Preeclampsia Diagnostics Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球妊娠毒血症诊断市场预计在预测期内将以 10.87% 的复合年增长率成长。

妊娠毒血症是一种高血压问题，由于尿液中蛋白质含量高（表示肾臟受损），会导致孕妇出现併发症。全球孕妇妊娠毒血症盛行率不断上升，增加了对诊断测试的需求，从而启动了妊娠毒血症诊断市场。此外，人们对併发症引起的风险因素的认识不断提高，加上政府采取的措施和增强预测的技术进步，预计将在预测期内进一步推动妊娠毒血症诊断市场的发展。

妊娠毒血症患者数量不断增加

由于血压调节不规律，全球妊娠毒血症患者数量不断增加，这是妊娠毒血症诊断市场的关键成长动力。根据美国国立卫生研究院的数据，妊娠毒血症併发症每年导致全球约 5 万名孕产妇死亡和约 50 万名胎儿死亡。此外，疾病预防控制中心估计，在美国20 至 44 岁的女性中，每年每 12 至 17 次怀孕中就有 1 人患有高血压。高血压现在在怀孕期间很常见，这是妊娠毒血症的一个迹象。即使在怀孕后，妊娠毒血症也会为女性带来问题，这表明需要预防和妊娠毒血症诊断测试​​。

母亲和婴儿的多种危险因素

由于妊娠毒血症对母亲和胎儿都有各种副作用，因此需要妊娠毒血症的治疗，并且正在推动妊娠毒血症诊断市场的发展。妊娠毒血症会导致早产、呼吸和餵食问题，在极少数情况下还会损害母亲和婴儿的健康。婴儿可能患有子宫内生长受限 (IUGR)，各种研究表明出生时患有 IUGR 的儿童成年后更容易患糖尿病、郁血性心臟衰竭和高血压。根据妊娠毒血症基金会的数据，每年出生的 3,000 万名婴儿中约有 15% 患有妊娠毒血症。

政府和其他机构的意识计划

旨在提高对妊娠毒血症併发症认识的政府计划正在推动妊娠毒血症诊断市场的发展。加州公共卫生部正在进行一项宣传宣传活动，将五月定为妊娠毒血症症意识月。此外，该国的孕产妇、儿童和青少年健康（MCAH）部门以多种语言提供有关妊娠毒血症的体征和症状的信息，包括阿拉伯语、中文、英语、波斯语、韩语、西班牙语-他加禄语和越南语。存在以提高认识。此外，各种组织的宣传活动也预计将推动妊娠毒血症诊断市场的发展。

技术进步与创新

医疗保健产业的技术进步正在提高妊娠毒血症检测的准确性并推动妊娠毒血症诊断市场的发展。 2023 年 3 月，北威尔斯引入了一项创新的面对面胎盘生长因子测试，以减少死产和早产。该测试只需 15 分钟即可测量 PLGF 水平，并允许孕妇根据风险快速进行分类。此外，Ascertain 和 Caire Health（Northwell Health 和 Aegis Ventures 的合资企业）宣布了一种新演算法来预测妊娠毒血症并解决日益恶化的死亡率问题。 Ascertain 的演算法比目前的预测标准提高了 10-15%。该公司的创投也表示，妊娠毒血症是可以透过机器学习来治疗的。

市场机会

孕妇高血压盛行率的增加为扩大妊娠毒血症诊断市场提供了机会。此外，医疗保健产业的投资前景为进入妊娠毒血症诊断市场提供了巨大的机会。例如，Mirvie 在 B 轮融资中筹集了 6,000 万美元，用于开发妊娠毒血症检测的创新设备。先兆子痫基金会的 Vision Grant 计画每年提供高达 25,000 美元的资金，用于妊娠毒血症、HELLP 症候群和相关妊娠高血压症候群的研究。此外，透过各种宣传计划提高孕妇的认识以及提高诊断测试的可及性也有望推动妊娠毒血症诊断市场的发展，并为市场扩张提供机会。

北美预计将成为主导市场

预计在预测期内，北美地区将在全球妊娠毒血症诊断市场中占据重要份额。造成这一比例的因素包括该地区妊娠毒血症併发症的增加以及女性采用妊娠毒血症诊断测试的意识提高。例如，根据妊娠毒血症基金会的数据，过去 20 年来，美国妊娠毒血症的盛行率增加了 25%。此外，最近的技术开拓以及 Quidel Corporation 和 Prestige Brands Holdings 等市场领导的存在进一步增强了该地区妊娠毒血症诊断市场的潜力。

妊娠毒血症诊断市场参与者

Atlas Medical成立于1996年，提供高品质的诊断剂和套件。该公司提供用于检测甲状腺和不孕症领域关键激素的 HCG 乳胶套件，以及用于孕妇的独立袋装 HCG 检测盒。 EKF Diagnostics Holdings 专注于即时检测、中心实验室检测、酵素製造和契约製造。该公司提供血红蛋白分析仪来识别患有妊娠期糖尿病的女性并控制病情。

主要市场开拓

2022 年 5 月，Metabolomics Diagnostics 将与子痫前症基金会合作，透过创建准确且偏差较小的测试来改善妊娠毒血症的预测。此外，此伙伴关係旨在透过教育和预防不良后果来改善孕产妇健康。 2021年6月，Lifecell在印度启动了早发性和晚发性妊娠毒血症筛检。该公司已成为印度第一家提供早发和晚发筛检的提供者。筛检小组现在包括额外的 Sflt-1 生物标记物，即使在怀孕晚期也有助于准确诊断。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章妊娠毒血症诊断市场：依测试类型

  • 介绍
  • 验血
  • 尿液检查
  • 其他的

第六章妊娠毒血症诊断市场：依产品和服务分类

  • 介绍
  • 用具
  • 试剂及耗材
  • 服务

第七章妊娠毒血症诊断市场：依最终使用者分类

  • 介绍
  • 医院
  • 诊断中心
  • 其他的

第八章妊娠毒血症诊断市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Thermo Fisher Scientific
  • BioMerieux SA
  • Atlas Medical
  • Quidel Corporation
  • Swiss Precision Diagnostics（SPD）GmbH
  • NG BIOTECH SAS
简介目录
Product Code: KSI061615658

The global preeclampsia diagnostics market is expected to grow at a CAGR of 10.87% during the forecast period.

Preeclampsia is a hypertensive problem that creates complex problems in pregnant women by high levels of protein in urine indicating kidney damage. The growing prevalence of preeclampsia in pregnant women globally is creating a demand for diagnostic tests thereby boosting the preeclampsia diagnostics market. Moreover, the rising awareness about the risk factors from the complication coupled with government initiatives and technological advancements for enhanced prediction is further contemplated to boost the preeclampsia diagnostics market throughout the forecast period.

Growing Prevalence of Preeclampsia Cases

The rising number of global preeclampsia cases due to irregular regulation of blood pressure is a major growth driver of the preeclampsia diagnostics market. According to National Institute of Health, around 50,000 maternal deaths and 500,000 fetal deaths occur each year worldwide due to preeclampsia complications. Moreover, hypertension occurs in 1 in every 12 - 17 pregnancies each year for women aged 20-44 years in the US as per the CDC estimates. High blood pressure is very common nowadays in pregnancy which is a defining feature of preeclampsia. Preeclampsia may create problems for women even after pregnancy showing the need for prevention and need for preeclampsia diagnostics tests thereby it is expected to drive the preeclampsia diagnostics market.

Multiple Risk Factors for Mother and Baby

There are various side effects of preeclampsia both on mother and baby and thus, it is required to treat the preeclampsia thereby it propels the preeclampsia diagnostics market. It may cause preterm births which increase breathing and feeding problems and in rare cases, it may result in maternal and infant health. Babies may suffer from Intrauterine Growth Restriction (IUGR) and various studies have shown that children born with IUGR are more prone to diabetes, congestive heart failure, and hypertension in their adult age. According to the Preeclampsia Foundation, around 15% of 30 million infants born each year are associated with preeclampsia.

Government and Other Institutions' Awareness Program

The government programs to raise awareness about preeclampsia complications are driving the preeclampsia diagnostics market. The California Department of Public Health runs a communication campaign in May as a preeclampsia awareness month. Moreover, the Maternal, Child, and Adolescent Health (MCAH) division of the country created a social media presence to increase awareness about signs and symptoms of preeclampsia in several languages including Arabic, Chinese, English, Farsi, Korean, Spanish Tagalog, and Vietnamese. Additionally, the campaigns by various organizations are also expected to boost the preeclampsia diagnostics market. For instance, the Check Know Share campaign was launched by Preeclampsia Foundation in May 2020 to urge pregnant women to check their blood pressure, know and understand their numbers and share with their healthcare provider. This was also the theme of the preeclampsia awareness month of 2020.

Technological Advancements and Innovation

The technological advancements in the healthcare industry, enhancing the precision of preeclampsia test is boosting the preeclampsia diagnostics market. In March 2023, an innovative in-person placental growth factor test was introduced in North Wales which reduces stillbirths and pre-term deliveries. This test measures PLGF levels in just 15 minutes and enables quickly segmenting pregnant women by risk. Moreover, a new algorithm for predicting preeclampsia and tackling worsening mortality rates was announced by Ascertain and Caire Health (Joint Venture by Northwell Health and Aegis Ventures). Ascertain's algorithm showed a 10-15% increase over current predictive standards. The company's VC also said that preeclampsia is extremely addressable with machine learning.

Opportunities in the Market

The growing prevalence of hypertension in pregnant women provides a good opportunity for preeclampsia diagnostics market expansion. Moreover, investment prospects in the healthcare industry provide a major opportunity to enter the preeclampsia diagnostics market. For instance, Mirvie raised $60 million in series B funding for the development of breakthrough devices for preeclampsia tests. The Vision Grant Program by Preeclampsia Foundation provides financial help of up to $25,000 every year to study preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy. Further, the rising awareness among pregnant women due to various awareness programs and increased accessibility to diagnostic tests is also anticipated to propel the preeclampsia diagnostics market thereby providing an excellent opportunity for market expansion.

North America is an Expected Dominant Market

The North American region is expected to hold a significant share of the global preeclampsia diagnostics market during the forecasted period. Various factors attributed to such a share are rising preeclampsia complications in the region and rising awareness among women to adopt the preeclampsia diagnostics test. For instance, the prevalence rate of preeclampsia has increased by 25% in the last two decades in America as per the Preeclampsia Foundation. Moreover, the recent technological developments and presence of market leaders such as Quidel Corporation and Prestige Brands Holdings further enhance the scope of the preeclampsia diagnostics market in the region.

Preeclampsia Diagnostics Market Players

  • Atlas Medical, founded in 1996 is a supplier of quality diagnostic reagents and kits. The company provides HCG latex kits to detect major hormones in the fields of thyroid and fertility, and HCG test cassettes, individually pouched for pregnant women.
  • EKF Diagnostics Holdings PLC focuses on point-of-care testing, central laboratory tests, enzyme manufacturing, and the provision of contract manufacturing. The company offers a range of hemoglobin analyzers to identify women with gestational diabetes and helps in managing their condition.

Key Market Development

  • In May 2022, Metabolomics Diagnostics entered into a partnership with Preeclampsia Foundation to improvise preeclampsia prediction by creating precise and less biased tests. Moreover, the partnership aims to improve maternal health by educating and preventing bad outcomes.
  • In June 2021, LifeCell launched screening for both early-onset and late-onset preeclampsia screening in India. The company became the first provider in India to offer screening for the early and late-onset. There is an addition of the Sflt-1 biomarker in the screening panel to help in accurate diagnosis even in the third trimester.

Segmentation:

By Test Type

  • Blood Test
  • Urine Test
  • Others

By Products & Services

  • Instruments
  • Reagents & Consumables
  • Services

By End-User

  • Hospitals
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. PREECLAMPSIA DIAGNOSTICS MARKET, BY TEST TYPE

  • 5.1. Introduction
  • 5.2. Blood Test
  • 5.3. Urine Test
  • 5.4. Others

6. PREECLAMPSIA DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Consumables
  • 6.4. Services

7. PREECLAMPSIA DIAGNOSTICS MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Diagnostic Centers
  • 7.4. Others

8. PREECLAMPSIA DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Thermo Fisher Scientific
  • 10.2. BioMerieux SA
  • 10.3. Atlas Medical
  • 10.4. Quidel Corporation
  • 10.5. Swiss Precision Diagnostics (SPD) GmbH
  • 10.6. NG BIOTECH SAS